Is 2014 Going to Be GlaxoSmithKline's Year?

After a strong 2013, can GlaxoSmithKline perform just as well in 2014?

Mar 1, 2014 at 11:45AM

As a whole host of its Pharmaceutical peers struggle to come to terms with patent expiries and generic competition, GlaxoSmithKline (NYSE:GSK) seems to be going from strength to strength.

Indeed, were it not for the ongoing bribery allegations in China pulling shares back over the past year, their outperformance of the S&P could have been even greater. As it was, shares in GlaxoSmithKline have posted gains of 24% over the past 12 months, while the S&P is not too far behind on 22%.

The story in 2014 has been slightly better for investors in GlaxoSmithKline, though, since its shares are up over 5% and the S&P 500 is struggling to make any gains, being flat so far. Can GlaxoSmithKline keep ahead of the S&P 500 and even extend its lead in 2014?

Upbeat news flow
Recent news flow for GlaxoSmithKline has been positive, with the company receiving positive opinions recommending marketing authorization from the European Medicine Agency's Committee for Medicinal Products for Human Use, or the EMA's CHMP. The two opinions relate to the same condition, chronic obstructive pulmonary disease, with the first being a once-daily, maintenance treatment for the disease called Incruse, while the second is a once-daily, maintenance bronchodilator treatment for the symptoms called Anoro.

GlaxoSmithKline expects the final decision regarding marketing authorization in the next few months, and it looks likely (although not definite) that it will be granted, since positive opinions by the CHMP are usually followed by approval.

In addition to recent positive news flow, GlaxoSmithKline also reported a strong set of annual results. They showed that core earnings per share increased by 4% in 2013, while the company continues to deliver a highly impressive performance with regard to its pipeline. Indeed, of the six drugs that GlaxoSmithKline highlighted as key drivers of growth at the start of 2013, five were approved and the sixth, albiglutide (used to treat type 2 diabetes), received a positive opinion from the EMA's CHMP.

This pipeline strength and the impressive volume of new approvals provides evidence as to why GlaxoSmithKline has been able to cope with patent expiry and generic competition much better than many of its Pharmaceutical peers.

Strength elsewhere
Of course, its peers are also experiencing positive news flow, too. For instance, AbbVie (NYSE:ABBV) has had a successful first year as an independent company, with it announcing the completion of its phase 3 hepatitis C virus, or HCV, studies on Jan. 31. The news was positive, with patients enrolled in the trials sustaining relatively high responses to treatments.

In addition, AbbVie also announced positive top-line phase 3 HCV results from the SAPPHIRE-I and SAPPHIRE-II studies during the fourth quarter of 2013, as well as the initiation of two further phase 3 trials, which highlights the potential the company has in its mid- and late-stage pipeline assets.

Meanwhile, AstraZeneca (NYSE:AZN) is fast coming to terms with its patent cliff. It has made a number of acquisitions, including the notable deal to purchase Bristol-Myers Squibb's (NYSE:BMY) share of its diabetes alliance for $2.7 billion. It also has the financial firepower (through having only a moderate level of debt -- the company's debt-to-equity ratio is just 44%) to make further acquisitions and also to reinvest in the business to improve the strength of its pipeline.

Looking ahead
So with recent results highlighting the strength of its pipeline, GlaxoSmithKline looks all set to have another strong year in 2014. With updates regarding marketing authorization for multiple drugs due in the next few months, shares could continue to outperform the S&P 500 through 2014 and deliver another great year for shareholders.

Could 2014 also be the year for this top stock?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens owns shares of AstraZeneca and GlaxoSmithKline. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information